Alyeska Investment Group
EBAC

Alyeska Investment Group’s European Biotech Acquisition Corp. Class A Ordinary Shares EBAC Stock Holding History

Alyeska Investment Group’s Portfolio EBAC Stock Details EBAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-150,000
Closed -$1.51M – 577
2022
Q4 		$1.51M Hold
150,000
– – 0.02% 335
2022
Q3 		$1.49M Hold
150,000
– – 0.02% 335
2022
Q2 		$1.47M Hold
150,000
– – 0.02% 442
2022
Q1 		$1.46M Hold
150,000
– – 0.02% 469
2021
Q4 		$1.45M Hold
150,000
– – 0.02% 488
2021
Q3 		$1.45M Hold
150,000
– – 0.02% 555
2021
Q2 		$1.46M Buy
+150,000
New +$1.47M 0.02% 550

Alyeska Investment Group's EBAC Position: Q1 2023 in Review

Alyeska Investment Group sold out of European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) in Q1 2023, closing a stake of 150,000 shares — an estimated $1.51M sold.

Alyeska Investment Group first reported a position in EBAC in Q2 2021 and held it in 7 quarters. The position peaked at $1.51M in Q4 2022. 0 funds tracked by Wall St. Rank hold EBAC as of Q1 2023.

  • Alyeska Investment Group reported no remaining European Biotech Acquisition Corp. Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
  • Alyeska Investment Group sold 150,000 European Biotech Acquisition Corp. Class A Ordinary Shares shares in Q1 2023, an estimated $1.51M.
  • Alyeska Investment Group first reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares in Q2 2021 and held it in 7 quarters.
  • Alyeska Investment Group's European Biotech Acquisition Corp. Class A Ordinary Shares position peaked at $1.51M in Q4 2022.
  • 0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Class A Ordinary Shares as of Q1 2023.

Based on Alyeska Investment Group's 13F filing for Q1 2023, filed 15 May 2023.